Midive (Riociguat)

• Riociguat is indicated for pulmonary vascular diseases that involve elevated pulmonary arterial pressure.
• Pulmonary arterial hypertension: improves exercise capacity and delays clinical worsening.
• Chronic thromboembolic pulmonary hypertension: enhances functional class and reduces pulmonary vascular resistance.

• Riociguat binds to the heme‑containing subunit of soluble guanylate cyclase, stabilizing its active conformation. This increases the conversion of GTP to cyclic GMP, leading to relaxation of smooth muscle cells in the pulmonary arteries. The elevated cyclic GMP levels promote vasodilation, inhibit proliferation, and improve hemodynamics in the pulmonary circulation. The drug’s effect is independent of endogenous nitric oxide, allowing it to augment vasodilation even when nitric oxide synthesis is impaired.

Riociguat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache
• Dizziness
• Nausea

Serious or Rare Side Effects

• Severe hypotension
• Pulmonary hemorrhage
• Liver enzyme elevation

• When prescribing Riociguat, clinicians should consider several safety aspects.
• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: use with caution; liver function tests should be performed regularly.
• Hypotension: check blood pressure before initiation and periodically during treatment.
• Concomitant nitrates: avoid co‑administration due to risk of additive vasodilation.
• Pregnancy: avoid unless the potential benefit justifies the potential risk to the fetus.
• Store at room temperature: keep in the original container, protect from moisture and light.

Riociguat interacts with several medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid)

• Phosphodiesterase‑5 inhibitors: may cause severe hypotension.
• Nitrates and nitric‑oxide donors: